BACKGROUND: Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays. RESULTS: Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT-PCR was negative on swab (77.0%) or blood (88.4%; P = .46). Final definition of RT-PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT-PCR -ve, and 25/69 RT-PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT-PCR -ve with neutralizing antibody ≥160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P < .05), probably denoting a "golden period" for CCP collection (≤28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer. CONCLUSIONS: RT-PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti-nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody.
BACKGROUND:Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, humanT-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays. RESULTS: Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT-PCR was negative on swab (77.0%) or blood (88.4%; P = .46). Final definition of RT-PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT-PCR -ve, and 25/69 RT-PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT-PCR -ve with neutralizing antibody ≥160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P < .05), probably denoting a "golden period" for CCP collection (≤28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer. CONCLUSIONS: RT-PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti-nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody.
Authors: Arwa Z Al-Riyami; Thierry Burnouf; Mark Yazer; Darrell Triulzi; Levent Tufan Kumaş; Levent Sağdur; Nil Banu Pelit; Renée Bazin; Salwa I Hindawi; Maha A Badawi; Gopal K Patidar; Hem Chandra Pandey; Rahul Chaurasia; Roberta Maria Fachini; Patrícia Scuracchio; Silvano Wendel; Ai Leen Ang; Kiat Hoe Ong; Pampee Young; Jarkko Ihalainen; Antti Vierikko; Yan Qiu; Ru Yang; Hua Xu; Naomi Rahimi-Levene; Eilat Shinar; Marina Izak; Carlos Alberto Gonzalez; David Martin Ferrari; Paula Verónica Cini; Robby Nur Aditya; Ratti Ram Sharma; Suchet Sachdev; Rekha Hans; Divjot Singh Lamba; Lise Sofie H Nissen-Meyer; Dana V Devine; Cheuk Kwong Lee; Jennifer Nga-Sze Leung; Ivan Fan Ngai Hung; Pierre Tiberghien; Pierre Gallian; Pascal Morel; Khuloud Al Maamari; Zaid Al-Hinai; Hans Vrielink; Cynthia So-Osman; Vincenzo De Angelis; Pierluigi Berti; Angelo Ostuni; Giuseppe Marano; Michel Toungouz Nevessignsky; Magdy El Ekiaby; James Daly; Veronica Hoad; Sinyoung Kim; Karin van den Berg; Marion Vermeulen; Tanya Nadia Glatt; Richard Schäfer; Rita Reik; Richard Gammon; Melissa Lopez; Lise Estcourt; Sheila MacLennan; David Roberts; Vernon Louw; Nancy Dunbar Journal: Vox Sang Date: 2021-05-20 Impact factor: 2.996
Authors: Silvano Wendel; Kevin Land; Dana V Devine; James Daly; Renée Bazin; Pierre Tiberghien; Cheuk-Kwong Lee; Satyam Arora; Gopal K Patidar; Kamini Khillan; Willem Martin Smid; Hans Vrielink; Adaeze Oreh; Arwa Z Al-Riyami; Salwa Hindawi; Marion Vermeulen; Vernon Louw; Thierry Burnouf; Evan M Bloch; Ruchika Goel; Mary Townsend; Cynthia So-Osman Journal: Vox Sang Date: 2021-03-27 Impact factor: 2.996
Authors: Arwa Z Al-Riyami; Thierry Burnouf; Mark Yazer; Darrell Triulzi; Levent Tufan Kumaş; Levent Sağdur; Nil Banu Pelit; Renée Bazin; Salwa I Hindawi; Maha A Badawi; Gopal K Patidar; Hem Chandra Pandey; Rahul Chaurasia; Roberta Maria Fachini; Patrícia Scuracchio; Silvano Wendel; Ai Leen Ang; Kiat Hoe Ong; Pampee Young; Jarkko Ihalainen; Antti Vierikko; Yan Qiu; Ru Yang; Hua Xu; Naomi Rahimi-Levene; Eilat Shinar; Marina Izak; Carlos Alberto Gonzalez; David Martin Ferrari; Paula Verónica Cini; Robby Nur Aditya; Ratti Ram Sharma; Suchet Sachdev; Rekha Hans; Divjot Singh Lamba; Lise Sofie H Nissen-Meyer; Dana V Devine; Cheuk Kwong Lee; Jennifer Nga-Sze Leung; Ivan Fan Ngai Hung; Pierre Tiberghien; Pierre Gallian; Pascal Morel; Khuloud Al Maamari; Zaid Al-Hinai; Hans Vrielink; Cynthia So-Osman; Vincenzo De Angelis; Pierluigi Berti; Angelo Ostuni; Giuseppe Marano; Michel Toungouz Nevessignsky; Magdy El Ekiaby; James Daly; Veronica Hoad; Sinyoung Kim; Karin van den Berg; Marion Vermeulen; Tanya Nadia Glatt; Richard Schäfer; Rita Reik; Richard Gammon; Melissa Lopez; Lise Estcourt; Sheila MacLennan; David Roberts; Vernon Louw; Nancy Dunbar Journal: Vox Sang Date: 2021-05-20 Impact factor: 2.996
Authors: Stephan Schlickeiser; Tatjana Schwarz; Sophie Steiner; Kirsten Wittke; Nabeel Al Besher; Oliver Meyer; Ulrich Kalus; Axel Pruß; Florian Kurth; Thomas Zoller; Martin Witzenrath; Leif Erik Sander; Marcel A Müller; Carmen Scheibenbogen; Hans-Dieter Volk; Christian Drosten; Victor M Corman; Leif G Hanitsch Journal: Front Immunol Date: 2021-01-29 Impact factor: 7.561
Authors: Sixten Körper; Bernd Jahrsdörfer; Victor M Corman; Jan Pilch; Patrick Wuchter; Rainer Blasczyk; Rebecca Müller; Torsten Tonn; Tamam Bakchoul; Richard Schäfer; David Juhl; Tatjana Schwarz; Nina Gödecke; Thomas Burkhardt; Michael Schmidt; Thomas Appl; Hermann Eichler; Harald Klüter; Christian Drosten; Erhard Seifried; Hubert Schrezenmeier Journal: Transfus Med Hemother Date: 2021-04-21 Impact factor: 3.747